Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition.


Unlike solid tumors, the primary strategy for leukemia treatment is chemotherapy. However, leukemia chemotherapy is associated with adverse drug effects and drug resistance. Therefore, it is imperative to identify novel agents that effectively treat leukemia while minimizing adverse effects. The Raf/MEK/extracellular regulated kinase (ERK) and signal… (More)


  • Blog articles referencing this paper

  • Presentations referencing similar topics